Caplacizumab

Drug Profile

Caplacizumab

Alternative Names: ALX-0081; ALX-0681; Anti-von Willebrand factor Nanobody - Ablynx

Latest Information Update: 05 May 2017

Price : $50

At a glance

  • Originator Ablynx
  • Class Anticoagulants; Antithrombotics; Proteins
  • Mechanism of Action Platelet aggregation inhibitors; Von Willebrand factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Thrombotic thrombocytopenic purpura
  • Discontinued Thrombosis

Most Recent Events

  • 06 Jun 2017 Ablynx plans a phase I trial in healthy volunteers (IV) (SC) (NCT03172208)
  • 02 May 2017 Ablynx completes enrolment in the phase III HERCULES trial for Thrombotic thrombocytopenic purpura in USA, Australia, Austria, Belgium, Canada, Czech Republic, France, Hungary, Turkey, Israel, Italy, the Netherlands, Spain, Switzerland and the United Kingdom (NCT02553317)
  • 06 Feb 2017 Preregistration for Thrombotic thrombocytopenic purpura (Adjunctive treatment) in European Union (SC, IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top